Login to Your Account

Xenon, Novartis Enter $157M Deal For Obesity Compounds

By Karen Pihl-Carey

Wednesday, September 22, 2004
In a deal that could bring Xenon Pharmaceuticals Inc. $157 million in pre-commercial payments, Novartis Pharma AG agreed to research, develop and commercialize compounds from Xenon's SCD1 drug development program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription